RPRX RPRX
Company Profile ↓Company Overview
RPRX (RPRX) is a publicly traded company listed on with a market capitalization of $24.76B. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Maintains a net profit margin of 32.4%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $2.38B (+5.1% YoY); net profit $770.95M.
- Trailing 12 Months Year-on-year growth — revenue +5.1%, earnings -10.2%.
- 5-Year Trend Long-term compounding — revenue CAGR 4.8%, profit CAGR -9.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 4.80% |
| 1 Year: | 5.06% |
Compounded Profit Growth
| 5 Years: | -9.22% |
| 1 Year: | -10.25% |
Stock Price Performance
| 1 Year: | +58.96% |
| 6 Months: | +35.70% |
| 3 Months: | +15.00% |
| 1 Month: | -0.09% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)51.46 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Excellent profit margin of 32.4%.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Earnings shrank at -9.2% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 457.61M | 464.28M | 500.88M | 510.93M | 538.40M | 573.03M | 554.96M | 585.77M | 562.05M | 535.96M | 573.46M | 683.97M | 538.20M | 536.31M | 567.98M | 537.27M | 564.69M | 568.25M | 578.66M | 609.29M | 621.99M | 630.58M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 34.06M | 368.87M | 182.13M | 233.61M | -1.91M |
| Operating Income | 327.86M | 532.50M | 361.43M | 409.35M | 510.57M | 229.30M | 744.95M | 303.05M | 219.72M | 377.79M | 192.21M | 478.97M | 248.84M | 151.44M | -73.77M | 269.63M | 735.07M | 534.18M | 209.80M | 427.16M | 388.38M | 632.48M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 499.69M | 160.68M | 525.05M | 451.28M | 563.15M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 65.26M | 68.67M | 79.56M | 94.17M | 93.72M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 434.43M | 90.64M | 444.21M | 355.91M | 468.26M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Net Income | 151.71M | 408.98M | 71.24M | 442.07M | 290.63M | 69.12M | 440.78M | 101.93M | 51.76M | 304.50M | 142.65M | 340.75M | 227.62M | 72.11M | 4.78M | 102.00M | 543.99M | 239.35M | 30.18M | 288.22M | 214.21M | 294.69M |
| Diluted EPS | - | - | - | 0.09 | 0.79 | 0.18 | 1.08 | 0.24 | 0.12 | 0.70 | 0.32 | 0.76 | 0.50 | 0.16 | 0.01 | 0.23 | 1.21 | 0.41 | 0.05 | 0.51 | 0.38 | 0.53 |
| R&D Expense | 21.46M | 22.72M | 7.64M | 5.78M | 5.10M | 2.64M | 3.12M | 90.50M | 100.50M | 606.00K | 25.50M | 500.00K | 500.00K | 50.50M | 500.00K | 500.00K | 500.00K | 50.50M | 300.50M | 50.50M | - | 39.79M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.79B | 1.81B | 2.12B | - | 2.24B | 2.35B | 2.26B | 2.38B |
| Cost of Revenue | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | 1.31B | 862.40M | 971.13M | 818.67M |
| Operating Income | 1.36B | 2.62B | 1.60B | - | 922.89M | 1.49B | 1.29B | 1.56B |
| EBITDA | - | - | - | - | 423.69M | 1.89B | 1.56B | 1.64B |
| Interest Expense | - | - | - | - | 187.96M | 187.19M | 225.51M | 307.66M |
| Pretax Income | - | - | - | - | 230.06M | 1.70B | 1.33B | 1.32B |
| Tax Provision | - | - | - | - | 0 | 0 | 0 | 0 |
| Net Income | 1.38B | 2.35B | 975.04M | - | 42.83M | 1.13B | 858.98M | 770.95M |
| Diluted EPS | - | - | 1.32 | - | 0.10 | 2.53 | 1.45 | 1.37 |
| R&D Expense | 392.61M | 83.04M | 26.29M | 200.08M | 177.11M | 52.00M | 2.00M | 452.00M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 12.45B | 16.02B | - | 16.81B | 16.38B | 18.22B | 19.62B |
| Current Assets | - | - | - | - | - | 2.55B | 1.27B | 1.80B | 1.53B |
| Cash & Equivalents | - | - | 246.20M | 1.01B | - | 1.71B | 477.01M | 929.03M | 618.70M |
| Inventory | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | 36.60M | 22.41M | 26.96M | 29.32M |
| Total Liabilities | - | - | 6.31B | 6.12B | - | 7.29B | 6.30B | 7.88B | 9.91B |
| Current Liabilities | - | - | 333.42M | 307.89M | - | 1.17B | 161.38M | 1.25B | 636.21M |
| Long Term Debt | - | - | 5.96B | 5.82B | - | 6.12B | 6.14B | 6.61B | 8.57B |
| Total Debt | - | - | - | - | - | 7.12B | 6.14B | 7.61B | 8.95B |
| Total Equity | 4.46B | 4.55B | 6.14B | 9.90B | - | 5.63B | 6.53B | 6.95B | 6.48B |
| Shares Outstanding | - | - | - | - | - | 443.17M | 446.69M | 445.99M | 428.67M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 1.62B | 1.67B | 2.03B | - | 2.14B | 2.99B | 2.77B | 2.49B |
| Investing Cash Flow | 303.42M | -2.15B | -2.76B | - | -1.03B | -2.07B | -2.68B | -1.61B |
| Financing Cash Flow | -1.38B | -1.19B | 1.49B | - | -944.86M | -2.15B | 361.14M | -1.19B |
| Capital Expenditure | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | 2.14B | 2.99B | 2.77B | 2.49B |
| Net Change in Cash | - | - | - | - | 169.70M | -1.23B | 452.02M | -310.33M |
| Share Buybacks | 0 | 4.27M | 0 | 0 | 0 | 304.76M | 229.65M | 1.23B |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - |
| Operating Margin % | 76.0% | 144.6% | 75.2% | - | 41.3% | 63.4% | 57.1% | 65.6% |
| Net Margin % | 76.8% | 129.4% | 45.9% | - | 1.9% | 48.2% | 37.9% | 32.4% |
| ROE % | 30.3% | 38.2% | 9.9% | - | 0.8% | 17.4% | 12.4% | 11.9% |
| ROCE % | - | 21.6% | 10.2% | - | 5.9% | 9.2% | 7.6% | 8.2% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for RPRX
$RPRX ($RPRX) Releases Q2 2026 Earnings - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMihwFBVV95cUxNMGlYWmdIQXBPUnpkbEJzX0R0b2NrQnRmWnBqM2hNWUZzREhHNWl0T3VRaGZJVnhUcjV0S2ZwVFRzeHVrNXI4UW53TGFhaHA5dkROeXQybmxSMV9ZWW53WXJyM0dqeFRWMi1zb1FobzJPam5IY3NTTUYyVXdydkluMkxDVDlxODQ?oc=5" …
Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxOM3pETWVSMlRaWV94U3FfVUIzYTRHR0g5Sl83SjE2ZVlMRVB6a0RLNFpmanFMQ1BEcHlNUG5EOXozVkdTLTNvNm9zVEdLWkd3cUFxRHhna2lSNUI0NDd3NWVLcGZkNXF3a3BrNXRBMXFLRFNvck94cUkwVHpDZ0w4eTljZTFpR0ZzZnlEZl…
Royalty Pharma raises 2026 receipts outlook to $3.4B-$3.5B - Stock Titan
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxOdzJMc1ZSRVR4cndkT2Y1Wk0taURjQUphZ08tcFlweXA5Yk5QY2czMHUtdUYxaTdSSnRGS09weWNWMlZURHVtT1pQQlZNb0F3S1FFVDRrMXhMZzFraDhlcXZFMFl4WVh1NUprS1hTUDdsMEFZS0JGSEZ1MEFwNkdFcTV0RXVvVm5TbDMtMz…
Lazard Asset Management LLC Sells 108,947 Shares of Royalty Pharma PLC $RPRX - MarketBeat
<a href="https://news.google.com/rss/articles/CBMi0AFBVV95cUxQOTFVU05kd1hYckhjYVhzZW5SU01JMEZ1SjJFUUxvMXUzV3J1VFN2TkR3WjE5RWpDaDN6SjlUUFA1ZWFKSEl2aEpFa0UtX0JsaldrVkNGX1Iyd0dGZE9TTC0xQURvenNPN19ZZy1vOHVVeUF5TGs1ZUJqR3l2UE9HejlITllNUVlaaHRXQl…
BofA raises Royalty Pharma stock price target on strong results - Investing.com
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxPczJTVnR4RzRXaWRaTVR1TEZDeEZPRElna3pzMTlpb1g1MEVQQms0ZFhrSDN1Z3RrcmJ6cVl1TUJGSW5aRUp3QnhLZnNpZUpzODV1dFdUR2lCdVJnUUNIN01HZWRidWdXTk1LVzYxb2tCQ0dqNE0wZlJaUURPb2xXS2pLODh0eTBZWXJSbF…
Royalty Pharma: At The Right P/E, I'm In (But Not Here) (NASDAQ:RPRX) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxPeDZjU2lRc2NvSjF5OHppd1BTcHNvUXZVUXpNUGFjYzVmMUR4ckc3YjliODFITm9uNzJObUR6U1p5UGlqNUpQOWw1Qk11ODY3NVh6V0NjLWlUaGJIdlpCOGNHNVVQRWdaaUt1dTlOcWx3ZVVnbzQxQUI0MXVDZE1mRFpJTWFVRXRCWnQ5TV…
RPRX — Frequently Asked Questions
What is the current share price of RPRX?
As of 2026-08-05 17:25 PDT, RPRX trades at $57.75 on NASDAQ/NYSE. Its 52-week range is $34.37 to $59.97.
What is the market capitalisation of RPRX?
RPRX has a market capitalisation of $24.76B on NASDAQ/NYSE.
What is the P/E ratio of RPRX?
RPRX trades at a trailing price-to-earnings (P/E) ratio of 42.25. Its price-to-book (P/B) ratio is 3.82.
What is the return on equity (ROE) of RPRX?
RPRX has a return on equity (ROE) of 11.90%. Its return on capital employed (ROCE) is 8.21%.
Is RPRX a good stock to buy?
This page provides a data-driven analysis of RPRX, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.